摘要
目的:评价普罗布考与阿托伐他汀联合对急性冠状动脉(冠脉)综合征患者的血脂、氧化低密度脂蛋白(OX-LDL)及炎症因子的影响。方法:122例急性冠脉综合征的患者随机分为单药治疗组(n=60,阿托伐他汀10 mg/d)和联合治疗组(n=62,阿托伐他汀10 mg/d+普罗布考500 mg/d)。分别于24小时内及治疗后4周、8周检测高敏C-反应蛋白(Hs-CRP)、氧化低密度脂蛋白、纤维蛋白原(FIB)、白介素6(IL-6)以及血脂六项,记录两组患者的不良反应发生情况。结果:治疗8周后联合治疗组的低密度脂蛋白胆固醇、载脂蛋白-B、氧化低密度脂蛋白、白介素6、高敏C-反应蛋白较单药治疗组下降更明显,差异有统计学意义(P<0.01)。通过多元相关分析,提示氧化低密度脂蛋白与高敏C-反应蛋白之间具有相关性(r=0.35,P<0.01)。结论:阿托伐他汀与普罗布考联合应用能更显著降低氧化低密度脂蛋白以及低密度脂蛋白胆固醇、载脂蛋白-B、高敏C-反应蛋白、白介素6的水平,可能通过降脂、抗炎、抗氧化的作用机制对稳定斑块有一定的作用。
Objective ： To evaluate the effect of probucol and atorvastatin combined medication on blood levels of oxidized low density lip- oprotein（OX-LDL） and inflammatory factors in patients with acute coronary syndrome（ACS）.
Methods： A total of 122 patients with acute coronary syndrome were randomly divided into two groups. Single medication group（ n = 60 ）, the patients were taken atorvastatin 10 mg/d; and combined medication group（ n = 62）, the patients were taken atorvastatin 10 mg/d with probucol 500 mg/d. Within 24 hours of medication, high sensitivity C-reactive protein（hsCRP） , OXLDL, fibrinogen（FIB） , interleukin 6（IL-6） and blood lipids were recorded, the above items were re-examined 4 weeks and 8 weeks after the medication respectively. The side effect was recorded and the difference between two groups was analyzed.
Results ： Compared with single medication group, 8 weeks after the medication, low-density lipoprotein cholesterol （ LDL- C） , apolipoprotein B, OX-LDL, IL-6 and hsCRP were significantly decreased in combined medication group（ P 〈 0. 01 ）. Multivariate analysis indicated that there was a relationship between OX-LDL and hsCRP（ r = 0. 35, P 〈 0. 01 ）.
Conclusion：Probucol and atorvastatin combined medication could significantly decrease the blood levels of OX-LDL, LDL- C, hsCRP, IL-6 and apolipoprotein B. It demonstrated that decreased level of blood lipids and anti-inflammation, anti-oxidation might stabilize the plaques in ACS patients and therefore reduce the risk of ACS.
出处
《中国循环杂志》
CSCD
北大核心
2008年第6期426-429,共4页
Chinese Circulation Journal
